W. Ho

发表

Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

J. Blattman, P. Greenberg, C. Yee, 2003, Cancer cell.

Chapuis Activity and Persist in Post-Transplant Patients T Cells Can Mediate Antileukemic + Transferred WT 1-Reactive CD 8

Thomas M. Schmitt, J. Radich, M. Bar, 2013 .

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

J. Vose, J. Friedberg, B. Cheson, 2014, Clinical immunology.

In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

P. Greenberg, W. Ho, J. Kuball, 2006, Journal of immunological methods.

Induction of autoimmune disease in mice by germline alteration of the T cell receptor gene expression.

P. A. Peterson, M. Davis, M. Toda, 1994, Journal of immunology.

Single-cell analysis of normal and FOXP 3-mutant human T cells : FOXP 3 expression without regulatory T cell development

A. Rudensky, H. Ochs, T. Torgerson, 2006 .

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

E. Lam, YounJeong Choi, J. Goldman, 2012 .

The XLR sequence family: dispersion on the X and Y chromosomes of a large set of closely related sequences, most of which are pseudogenes.

P. Avner, M. Davis, H. Garchon, 1989, Nucleic acids research.

DCDT 2980 S , an anti-CD 22-Monomethyl Auristatin E antibody-drug conjugate , is a potential treatment for non-Hodgkins Lymphoma

Jeffrey T. Lau, D. Danilenko, A. Ebens, 2013 .

Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA.

T. Shenk, J. Schaack, P. Freimuth, 1990, Genes & development.

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

Thomas M. Schmitt, J. Radich, M. Bar, 2013, Science Translational Medicine.

Construction and Preliminary Characterization of a Library of “Lethal” Preterminal Protein Mutant Adenoviruses

J. Schaack, J. Sussenbach, P. Freimuth, 1999, Journal of Virology.

Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells

M P Cooke, M. Cooke, M. Davis, 1994, The Journal of experimental medicine.

Therapeutic Potential of Cells of the Immune System

W. Ho, L. Lamb, 2020 .

Inhibition of thymocyte positive selection by natural MHC: peptide ligands

C Benoist, V. Kouskoff, C. Benoist, 1999, European journal of immunology.

Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.

P. Greenberg, J. Kuball, W. Ho, 2007, Blood.

CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells

Mark M. Davis, M. Cooke, C. Goodnow, 1995, Nature.

Adenovirus type 5 precursor terminal protein-expressing 293 and HeLa cell lines

J. Schaack, W. Ho, D. Ornelles, 1995, Journal of virology.

A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis.

M. Davis, C. Goodnow, W. Ho, 1997, Immunity.

Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

A. Rudensky, H. Ochs, T. Torgerson, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

P. Greenberg, C. Yee, W. Ho, 2002, The Journal of clinical investigation.

Adoptive therapy with CD8 + T cells

P. Greenberg, C. Yee, W. Ho, 2002 .

Investigational antibody-drug conjugates for hematological malignancies

V. Ramakrishnan, W. Ho, A. Polson, 2011, Expert opinion on investigational drugs.

Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Ralf-Holger Voss, P. Greenberg, M. Dossett, 2007, Blood.

antigen without requiring knowledge of epitope specificities T cells responding to + and expansion of the full repertoire of CD8 Activation-induced expression of CD137 permits detection, isolation,

P. Greenberg, J. Kuball, W. Ho, 2013 .

Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.

P. LoRusso, S. Piha-Paul, Christina Wu, 2019 .

548 Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma

Daniel M. Johnson, R. Goyal, W. Ho, 2021, Journal for ImmunoTherapy of Cancer.

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Jeffrey T. Lau, D. Danilenko, A. Ebens, 2013, Molecular Cancer Therapeutics.

An Analysis of T Cell Receptor–Ligand Interaction Using a Transgenic Antigen Model for T Cell Tolerance and T Cell Receptor Mutagenesis

Mark M. Davis, E. Rock, P. Patten, 1993 .

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

R. Advani, B. Cheson, Zheng Su, 2012 .

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

P. L. Bergsagel, S. Trudel, S. Singhal, 2012 .

Inhibition of thymocyte positive selection by natural MHC: peptide ligands

V. Kouskoff, C. Benoist, D. Mathis, 1999, European journal of immunology.

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

T. Kipps, W. Cosolo, I. Dyagil, 2012 .